

Notice to extraordinary general meeting in Magle Chemoswed Holding AB (publ)

The shareholders of Magle Chemoswed Holding AB (publ), org. no. 556913-4710 (the "Company"), are invited to an extraordinary general meeting (the "EGM") on 26 May 2026, at 15:00 CEST at the Company's premises at Agneslundsvägen 20B in Malmö, Sweden. The registration for the EGM starts at 14:30 CEST.

Right to participate

Shareholders who wish to participate in the EGM must:

- i. be entered in the register of shareholders maintained by Euroclear Sweden AB on 18 May 2026; and
- ii. no later than 20 May 2026, give notice of participation to the Company either by post to Magle Chemoswed Holding AB (publ), Agneslundsvägen 27, 212 15 Malmö, Sweden or via e-mail to stamman@maglechemoswed.com. When providing such notice, the shareholder shall state name, personal or corporate registration number, address, telephone number, and the number of any accompanying assistant (not more than two), as well as information about any proxy.

If a shareholder is represented by proxy, a written, dated proxy for the representative must be issued. A proxy form is available on the Company's website, www.maglegroup.com. If the proxy is issued by a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. To facilitate the registration at the EGM, the proxy and the certificate of registration or equivalent certificate of authority should be sent to the Company as set out above so that it is received no later than 20 May 2026.

Nominee-registered shares

In order to be entitled to participate in the meeting shareholders who have registered their shares in the name of a nominee must, in addition to announcing their intention to participate in the meeting, request that their shares be registered in their own name, so the shareholder is entered into the register of shareholders on 18 May 2026. This registration may be temporary (so-called voting right registration) and is requested by the nominee in accordance with the nominee's procedures and in advance as determined by the nominee. Voting right registrations completed no later than the second bank day after 18 May 2026, are considered when preparing the register of shareholders.

Proposed agenda

1. Opening of the EGM
2. Election of Chairman of the EGM
3. Preparation and approval of the voting list
4. Approval of the agenda
5. Election of one or two persons to verify the minutes

6. Determination as to whether the EGM has been duly convened
7. Determination of the number of board members
8. Election of board members
9. Determination of remuneration to be paid to the board members
10. Closing of the EGM

Resolution proposals

Item 7: Determination of the number of board members

The nomination committee, consisting of Hedda Lidgard, Joel Eklund and Morten Bergstrand (the "**Nomination Committee**"), proposes that the number of board members, for the period until the end of the next annual general meeting, shall be four, without any deputy board members.

Item 8: Election of board members

The Nomination Committee proposes that the following persons be elected as members of the board of directors: re-election of Stig Løkke Pedersen (chairman), Sven-Christer Nilsson and Mats Pettersson as board members and election of Søren Skjold Mogensen as a new board member, for the period until the end of the next annual general meeting. Malin Malmsjö has informed the Nomination Committee that she declines re-election.

Søren Skjold Mogensen

Born: 1971.

Education: Master of Science (Cand. Merc.), International Strategy & Marketing, Odense University, Managing New Product Innovation (SIMI, Mini MBA, Life science) SIMI, Copenhagen.

Background: SSI Diagnostica A/S, CEO & EVP, SSI Diagnostica A/S, Chief Commercial Officer (CCO), and various roles, including regional VP in H. Lundbeck A/S, Russia, CIS & Eastern Europe.

Other ongoing assignments: VP, Business Development and Commercial Operations, AJ Vaccines A/S.

Søren does not, currently, hold any shares in the Company and is independent in relation to the Company, its senior management and major shareholders.

Item 9: Determination of remuneration to be paid to the board members

The Nomination Committee proposes that the remuneration for each board member, appointed by the general meeting, shall amount to SEK 100,000 and that the remuneration to the chairman shall amount to SEK 200,000, for the period until the end of the next annual general meeting. The remuneration shall be paid proportionally in relation to the duration of the mandate period each board member has held the assignment.

Shareholders' right to obtain information

Shareholders are reminded of their right to, at the EGM, obtain information from the board of directors and CEO in accordance with Chapter 7, Section 32 of the Swedish Companies Act.

Available documentation

Documents in accordance with the Swedish Companies Act will be available at the Company and on the Company's website, www.maglegroup.com. The documents will also be sent to shareholders who wish to do so and state their postal address.

Processing of personal data

For information about the processing of your personal data, it is referred to the privacy notice available at Euroclear's webpage.

Magle Chemoswed Holding AB (publ)'s corporate registration number is 556913-4710 and its registered office is in Malmö, Sweden.

Malmö in May 2026

Magle Chemoswed Holding AB (publ)

The board of directors

Contacts Aaron

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmaceut.com and www.maglebiopolymers.com Redeye Nordic Growth AB is the company's Certified Adviser.

Attachments

[Notice to extraordinary general meeting in Magle Chemoswed Holding AB \(publ\)](#)